Ch.21.Cancer.2007.ppt

35
Ch. 21 h. 21. Cancer and the Immune System hat is cancer? hat is the immune response to cancer? hat are the prospects for immune therapies?

Transcript of Ch.21.Cancer.2007.ppt

Page 1: Ch.21.Cancer.2007.ppt

Ch. 21

Ch. 21. Cancer and the Immune System

What is cancer?

What is the immune response to cancer?

What are the prospects for immune therapies?

Page 2: Ch.21.Cancer.2007.ppt

Ch. 21

Cancer cells are out of control!

Usually derived from a single cell, forminga neoplasm, or tumor

Benign tumors are noninvasive; malignant tumors can invade and spread(metastasis)

Cancers are classified according to their originCarcinomas vs blood cell cancers:

leukemias and lymphomas

Page 3: Ch.21.Cancer.2007.ppt

Ch. 21 p. 526

Page 4: Ch.21.Cancer.2007.ppt

Ch. 21

How do cells become “transformed” intomalignant cells?

RadiationCarcinogensViruses

expression of oncogenes (aberrant versions of proto-oncogenes)

Page 5: Ch.21.Cancer.2007.ppt

Ch. 21

Types of regulatory genes

Proto-oncogenes- induce proliferation invarious ways

Tumor suppressors- inhibit cell proliferation

Regulators of apoptosis

Defects in any of these can lead to uncontrolledcell growth

Page 6: Ch.21.Cancer.2007.ppt

Ch. 21

p. 528

Page 7: Ch.21.Cancer.2007.ppt

Ch. 21

Mutations accumulate in these cells as theyare gradually converted to malignantcells

Translocations are associated with certainspecific tumors

Page 8: Ch.21.Cancer.2007.ppt

Ch. 21

p. 529

Page 9: Ch.21.Cancer.2007.ppt

Ch. 21

p. 529

Page 10: Ch.21.Cancer.2007.ppt

Ch. 21

p. 530

Page 11: Ch.21.Cancer.2007.ppt

Ch. 21

Immune system tumors

Solid or systemic?Acute or chronic?Immature or mature cells?Myelocytic or lymphocytic?

Page 12: Ch.21.Cancer.2007.ppt

Ch. 21

p. 531

Page 13: Ch.21.Cancer.2007.ppt

Ch. 21

Tumor-specific antigens (TSTA) - found only on tumorschemical or physical carcinogenssome viruses: e.g., ATLL, HPV

Adult T-Cell Leukemia/LymphomaHuman Papilloma Virus (types 16 & 18)

Tumor-associated antigens (TAA) - may be gene products that normally are not expressed(or at the abnormal levels seen in cancer)

Can these be isolated and used as vaccines?Diagnosis? Therapy?

Page 14: Ch.21.Cancer.2007.ppt

Ch. 21

p. 532

Page 15: Ch.21.Cancer.2007.ppt

Ch. 21

p. 534

Page 16: Ch.21.Cancer.2007.ppt

Ch. 21

Page 17: Ch.21.Cancer.2007.ppt

Ch. 21

p. 535

Page 18: Ch.21.Cancer.2007.ppt

Ch. 21

p. 536

Page 19: Ch.21.Cancer.2007.ppt

Ch. 21

Page 20: Ch.21.Cancer.2007.ppt

Ch. 21

Page 21: Ch.21.Cancer.2007.ppt

Ch. 21

Page 22: Ch.21.Cancer.2007.ppt

Ch. 21

Most tumor antigens are NOT unique to tumors

Often these are fetal proteins (e.g., growth factor receptors)

CEA- carcinoembryonic antigenAFP- alpha-fetoprotein

Oncogene proteins as tumor antigensNeu on human breast cancer cellsTATA’s on human melanomas: MAGE1,

MAGE-3, BAGE, GAGE-1, GAGE-2. Some shared with other tumors

Page 23: Ch.21.Cancer.2007.ppt

Ch. 21

p. 537

Page 24: Ch.21.Cancer.2007.ppt

Ch. 21

Immune response to tumors: Ab’s & CMI (after all, it’s altered self)

Cell-mediated response of major importance: CTL’s, NK cells (with or w/o ADCC), activated macrophages ~ regression (lytic enzymes, ROI, RNI, TNF-alpha)

Many tumors reduce MHC Class I expressionNK cells can kill these

Also macrophages add NK cells can attackantibody-coated tumor cells (ADCC)

Immune surveillance?

Page 25: Ch.21.Cancer.2007.ppt

Ch. 21

im

Tumors can evade immune response

Anti-tumor antibody can block T cell responses(enhance tumor growth)

Tumors can modulate antigens – “Ag modulation”(Ab’s bind to Ag on leukemic cells, induce capping, endocytosis of Ag, shedding of Ag-Ab complexes)

Tumors can reduce MHC Class I expression(selection; escape CTL recognition)

Tumors can reduce “second signal” expression(no B7 -> clonal anergy)

Page 26: Ch.21.Cancer.2007.ppt

Ch. 21

p. 539

Page 27: Ch.21.Cancer.2007.ppt

Ch. 21

Strategies for immunotherapy: adjuvant or cytokine

Make cells more immunogenicbetter CTL activation“vaccine” made up of cells?

Enhancement of APC activity can modulate tumor immunityBCG – attenuated Mycobacterium bovismouse dendritic cells incubated with GM-CSF

and tumor fragments, then into animal,activate anti-tumor Th and CTL’s

Page 28: Ch.21.Cancer.2007.ppt

Ch. 21

p. 540

Page 29: Ch.21.Cancer.2007.ppt

Ch. 21

Page 30: Ch.21.Cancer.2007.ppt

Ch. 21

Cytokine therapy

Many have been tried: thanks to recombinant DNA technologyinterferons (incr. MHC I, MHC II), tumor necrosis factors (TNF), IL-2, -4, -6, -12; GM-CSF

Problems:complexity of cytokine interactionshard to administershort half-lifeserious side effects

Page 31: Ch.21.Cancer.2007.ppt

Ch. 21

LAK cells (lymphokine-activated killer cells)grow blood cells in high levels of IL-2produce mostly NK cells (NOT tumor-specific)

TIL’s (tumor-infiltrating lymphocytes)may have more tumor-specific activityand need less IL-2

Page 32: Ch.21.Cancer.2007.ppt

Ch. 21

Monoclonal antibodies are useful in treating some tumors

Idiotype-specific for B-cell lymphoma: Levy (Stanford)

Humanized

Anti-HER2 for HER2-receptor-bearing breast cancer

Immunotoxins – mAb conjugated to ricin

Page 33: Ch.21.Cancer.2007.ppt

Ch. 21

p. 543

Page 34: Ch.21.Cancer.2007.ppt

Ch. 21

p. 542

Page 35: Ch.21.Cancer.2007.ppt

Ch. 21

Cancer vaccines?

Antigenic peptides (tumor-specific and immunogenic

Delivery (recombinant vaccines)

Will they be effectively presented to T cells?

Some viral vaccines (e.g., against HPV)may be helpful

There is much to be done.